TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9647303

Group type: EXPERIMENTAL
Intervention: MRC prognostic index score of 1-10
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: MRC prognostic index score of 11-15
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: MRC prognostic index score of 16-20
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: MRC prognostic index score of 21-25
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: MRC prognostic index score of 26-33
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: MRC prognostic index score of 34-38
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Anaplastic astrocytoma
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 236
Study: 7921323

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 491
Study: 2636680

Group type: EXPERIMENTAL
Intervention: Dietary protein restriction (DPR) group (0.4 to 0.6 g/kg/day)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Dietary protein restriction (DPR) group
Number of subjects: 248
Study: 360902

Group type: EXPERIMENTAL
Intervention: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 31154595

Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography (TEE) before and after marathon running
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Real time three-dimensional echocardiography (RT3DE)
Number of subjects: 212
Study: 28575010

Group type: EXPERIMENTAL
Intervention: HIV-infected women
Number of subjects: 1744

Group type: COMPARATOR
Intervention: HIV-uninfected women
Number of subjects: 1744
Study: 25989868

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 2 µg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa 10 µg/kg
Number of subjects: 0
Study: 22562545

Group type: EXPERIMENTAL
Intervention: Resistance training (50‐60 min of circuit weight training per day, 3 days a week, for 12 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study: 24501827

Group type: EXPERIMENTAL
Intervention: Thinking about death
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control topic (not specified)
Number of subjects: 0
Study: 19196366

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU per day)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 16650622

Group type: EXPERIMENTAL
Intervention: Incentive/reward intervention (cash lottery for BAC < 0.05)
Number of subjects: 702

Group type: COMPARATOR
Intervention: Control group (non-intervention parties)
Number of subjects: 702
Study: 15249347

Group type: EXPERIMENTAL
Intervention: beta-blocker therapy
Number of subjects: 0
Study: 11211198

Group type: EXPERIMENTAL
Intervention: CsA-NL (cyclosporine microemulsion)
Number of subjects: 380

Group type: COMPARATOR
Intervention: CsA-SM (oil-based formulation of cyclosporine)
Number of subjects: 380
Study: 9686458

Group type: EXPERIMENTAL
Intervention: Failure feedback
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Success feedback
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: No feedback
Number of subjects: 2
Study: 8036289

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide 100 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide 200 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide 400 micrograms
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2663319

Group type: EXPERIMENTAL
Intervention: Lacidipine (4 mg dose)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29129436

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 μg once daily)
Number of subjects: 680

Group type: COMPARATOR
Intervention: Risedronate (35 mg once weekly)
Number of subjects: 680
Study: 27147514

Group type: COMPARATOR
Intervention: recAP 200, 500, 1000 or 2000 U/kg (single dose)
Number of subjects: 51

Group type: COMPARATOR
Intervention: recAP 500 or 1000 U/kg (multiple doses)
Number of subjects: 51

Group type: COMPARATOR
Intervention: recAP (various doses)
Number of subjects: 51

Group type: COMPARATOR
Intervention: recAP (250, 500, 1000 U/kg once every 24h for three consecutive days)
Number of subjects: 51
Study: 24585907

Group type: EXPERIMENTAL
Intervention: Stapler closure
Number of subjects: 53

Group type: COMPARATOR
Intervention: Hand-sewn technique
Number of subjects: 53
Study: 22918614

Group type: EXPERIMENTAL
Intervention: Fosphenytoin sodium 22.5 mg/kg at an infusion rate of 3 mg/kg/min
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fosphenytoin sodium 30 mg/kg
Number of subjects: 0
Study: 21358898

Group type: EXPERIMENTAL
Intervention: Larger Incentive (LI) - $100 maximum incentive
Number of subjects: 57

Group type: COMPARATOR
Intervention: Smaller Incentive (SI) - $32 maximum incentive
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Descending payment schedule
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Escalating payment schedule
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Descending groups during first five visits
Number of subjects: 57
Study: 18081602

Group type: EXPERIMENTAL
Intervention: Laparoscopic Burch colposuspension
Number of subjects: 72

Group type: COMPARATOR
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study: 15721694

Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy (PRK) with Technolas 217C excimer laser
Number of subjects: 70
Study: 12214891

Group type: EXPERIMENTAL
Intervention: Salbutamol (sal)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ipratropium (ipra)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 44
Study: 10542894

Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 9324

Group type: COMPARATOR
Intervention: Control
Number of subjects: 9324
Study: 8907587

Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg, single oral dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental compounds (CGP-28238, Dup-697, NS-398, SC-58125, L-745,337)
Number of subjects: 0

Group type: COMPARATOR
Intervention: LPS (100 mu g/mL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PBS
Number of subjects: 0
Study: 1760907

Group type: EXPERIMENTAL
Intervention: Barium meal
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Upper gastrointestinal endoscopy
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Endoscopy with mild sedation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Clinical diagnosis
Number of subjects: 64

Group type: COMPARATOR
Intervention: Management change
Number of subjects: 64
Study: 6755682

Group type: EXPERIMENTAL
Intervention: Pressimmune (AHLG‐Behring) at 30 mg/kg/bdw for 21 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 30554828

Group type: EXPERIMENTAL
Intervention: Nabiximols (oromucosal spray containing 2.7 mg delta-9-tetrahydrocannabinol and 2.5 mg cannabidiol, self-titrated up to 12 actuations per 24 h for 6 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nabiximols
Number of subjects: 60
Study: 28421384

Group type: EXPERIMENTAL
Intervention: Guolin-Qigong (GLQG)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Physical stretching program (control group)
Number of subjects: 158
Study: 26031321

Group type: EXPERIMENTAL
Intervention: Mixture of PAHs (phenanthrene, fluoranthene, benzo(a)pyrene)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single contaminants (phenanthrene, fluoranthene, benzo(a)pyrene)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of PAHs (single compounds or mixtures)
Number of subjects: 0
Study: 25100138

Group type: EXPERIMENTAL
Intervention: Group A (5 mL/s and 90 mAs)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Group B (3.5 mL/s and 135 mAs)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Group C (5 mL/s and 135 mAs)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Group D (3.5 mL/s and 90 mAs)
Number of subjects: 119
Study: 23530423

Group type: EXPERIMENTAL
Intervention: Palivizumab (synagis)
Number of subjects: 0
Study: 19176684

Group type: EXPERIMENTAL
Intervention: rATG induction therapy
Number of subjects: 16
Study: 17696229

Group type: EXPERIMENTAL
Intervention: Dexrabeprazole 10 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Rabeprazole 20 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 15747040

Group type: EXPERIMENTAL
Intervention: Self-management group
Number of subjects: 202

Group type: COMPARATOR
Intervention: Family doctor group
Number of subjects: 202
Study: 12165717

Group type: EXPERIMENTAL
Intervention: Lorazepam as adjuvant therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 9707190

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis with rtPA
Number of subjects: 100
Study: 8542209

Group type: EXPERIMENTAL
Intervention: Stationary bicycling at home (exercise group)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 71
Study: 2229464

Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Flurazepam 15 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 433806

Group type: EXPERIMENTAL
Intervention: 36 g nitrogen diet
Number of subjects: 6

Group type: COMPARATOR
Intervention: 12 g nitrogen diet
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High protein diet
Number of subjects: 6
Study: 30944143

Group type: EXPERIMENTAL
Intervention: CONCERTO+ eHealth platform for chronic disease management, used for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 29890150

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with concurrent thoracic radiotherapy (50 Gy) followed by resection and postoperative consolidation chemotherapy
Number of subjects: 40
Study: 26389979

Group type: EXPERIMENTAL
Intervention: ReadySteady intervention
Number of subjects: 30
Study: 24650627

Group type: EXPERIMENTAL
Intervention: Laboratory-based emotion regulation (ER) training focusing on expressive suppression
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Laboratory-based emotion regulation (ER) training focusing on cognitive reappraisal
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Binge eating disorder (BED) group
Number of subjects: 81

Group type: COMPARATOR
Intervention: Overweight females without BED
Number of subjects: 81
Study: 21087399

Group type: EXPERIMENTAL
Intervention: Immediate loading with fixed bridges (test group, n=9)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Delayed loading (control group, n=9)
Number of subjects: 18
Study: 19272623

Group type: EXPERIMENTAL
Intervention: Cabergoline treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bicompartmental model
Number of subjects: 20

Group type: COMPARATOR
Intervention: Monocompartmental model
Number of subjects: 20
Study: 17785367

Group type: EXPERIMENTAL
Intervention: High fat-low carbohydrate (HF-LC) diet (66% fat, 4% carbohydrate)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Moderate fat-moderate carbohydrate (MF-MC) diet (35% fat, 35% carbohydrate)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: High fat-low carbohydrate (HF-LC) diet
Number of subjects: 23

Group type: COMPARATOR
Intervention: Moderate fat-moderate carbohydrate (MF-MC) diet
Number of subjects: 23
Study: 15185765

Group type: EXPERIMENTAL
Intervention: EC‐IC bypass with risk factor modifications
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-surgical group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical group
Number of subjects: 0
Study: 11453955

Group type: EXPERIMENTAL
Intervention: GH administration (1.80 +/- 0.24 IU/day) for 12 weeks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: GH administration
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: GH discontinuation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 16
Study: 9483598

Group type: EXPERIMENTAL
Intervention: Propofol with nitrous oxide (70%)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propofol without nitrous oxide (O2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Halothane/nitrous oxide (70%)
Number of subjects: 60
Study: 8304304

Group type: EXPERIMENTAL
Intervention: H. pylori infection present
Number of subjects: 181
Study: 2656134

Group type: EXPERIMENTAL
Intervention: Lactitol
Number of subjects: 31

Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 31
Study: 5413950

Group type: EXPERIMENTAL
Intervention: Ergotamine tartrate (0.25 mg. intravenously)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ergometrine maleate (0.25 mg. intravenously)
Number of subjects: 0
Study: 28436015

Group type: EXPERIMENTAL
Intervention: 5% topical minoxidil solution applied twice daily to fingernails
Number of subjects: 32

Group type: COMPARATOR
Intervention: Untreated nails
Number of subjects: 32
Study: 25752476

Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Replacement (TAVR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical Aortic Valve Replacement
Number of subjects: 0
Study: 22999803

Group type: EXPERIMENTAL
Intervention: CPD planning worksheets (test group)
Number of subjects: 105

Group type: COMPARATOR
Intervention: No specific intervention (control group)
Number of subjects: 105
Study: 22089302

Group type: EXPERIMENTAL
Intervention: Exercise at 80% maximal intensity for 20 min
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Exercise at 60% maximal intensity for 40 min
Number of subjects: 14
Study: 19023932

Group type: EXPERIMENTAL
Intervention: BIS monitoring group (n = 78)
Number of subjects: 156

Group type: COMPARATOR
Intervention: No-BIS monitoring group (n = 78)
Number of subjects: 156
Study: 16467096

Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m2 (10‐minute i.v. infusion) on day 1 of a 21‐day cycle with folic acid and vitamin B12 supplementation
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m2
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Pemetrexed chemotherapy
Number of subjects: 61
Study: 12620606

Group type: EXPERIMENTAL
Intervention: Remifentanil (mu-opioid agonist) administered via computer-controlled infusion targeting plasma concentrations between 0 and 6 ng/ml.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Freezing the skin (experimental model of hyperalgesia).
Number of subjects: 12
Study: 17118044

Group type: EXPERIMENTAL
Intervention: Standard care plus consultations with a specialist prenatal care nurse
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Standard care plus nurse consultations and a home visitor
Number of subjects: 284

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 284
Study: 10490109

Group type: EXPERIMENTAL
Intervention: 585-nm flashlamp-pumped pulsed-dye laser
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Silicone gel sheeting
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (untreated sections)
Number of subjects: 20
Study: 8744657

Group type: EXPERIMENTAL
Intervention: Morphine (2 mg loading dose, 0.5 mg boluses, 0.2 mg/h infusion)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fentanyl (60 micrograms loading dose, 25 micrograms boluses)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fentanyl plus morphine (F/M group)
Number of subjects: 30
Study: 1743226

Group type: EXPERIMENTAL
Intervention: Intravesical mitomycin C (MMC)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Bacillus Calmette‐Guérin (BCG)
Number of subjects: 91
Study: 7020108

Group type: EXPERIMENTAL
Intervention: Penbutolol 40 mg daily for 7 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Penbutolol 4 mg intravenous
Number of subjects: 0
Study: 31524123

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Non-LNS (multiple micronutrients (MMN) + iron and folic acid (IFA))
Number of subjects: 375
Study: 27879499

Group type: EXPERIMENTAL
Intervention: MFCL N (center-near)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Bifocal
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: MFCL D (center-distance)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (single vision)
Number of subjects: 17
Study: 25665004

Group type: EXPERIMENTAL
Intervention: Stable Plyometric Training (SPT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Highly Unstable Plyometric Training (IPT)
Number of subjects: 24
Study: 24893708

Group type: COMPARATOR
Intervention: 40 mg atomoxetine
Number of subjects: 25
Study: 22956850

Group type: EXPERIMENTAL
Intervention: Optimal Noise (ON)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Zero Noise (ZN)
Number of subjects: 8

Group type: COMPARATOR
Intervention: High Noise (HN)
Number of subjects: 8
Study: 19236162

Group type: EXPERIMENTAL
Intervention: LC1 (pseudomanic behavior)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: LC2 (cognitive)
Number of subjects: 252

Group type: COMPARATOR
Intervention: LC3 (pseudodepressed behavior)
Number of subjects: 252
Study: 17170019

Group type: EXPERIMENTAL
Intervention: Diet and exercise (DE) counselling group intervention
Number of subjects: 2022
Study: 15325894

Group type: EXPERIMENTAL
Intervention: Colposcopy done twice by a single examiner
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: AviScope examination
Number of subjects: 14

Group type: COMPARATOR
Intervention: Naked eye inspection
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Colposcopy done by two examiners
Number of subjects: 14
Study: 11795343

Group type: EXPERIMENTAL
Intervention: 20 mg/day of tamoxifen
Number of subjects: 5408

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5408
Study: 9625100

Group type: EXPERIMENTAL
Intervention: 500 mg Ca as calcium carbonate twice daily with meals for 6 months
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo twice daily with meals for 6 months
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Lactating women
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Lactating women after weaning
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Women previously lactating
Number of subjects: 187
Study: 8043313

Group type: EXPERIMENTAL
Intervention: Intravenous pyridoxine (1 g dose)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 108
Study: 31556668

Group type: EXPERIMENTAL
Intervention: Enhanced counseling for pain coping skills
Number of subjects: 148

Group type: COMPARATOR
Intervention: Standard counseling
Number of subjects: 148
Study: 28437795

Group type: EXPERIMENTAL
Intervention: HEART care
Number of subjects: 3648

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3648
Study: 26700304

Group type: EXPERIMENTAL
Intervention: Ipilimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 0
Study: 23343224

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen for 2 years
Number of subjects: 564

Group type: COMPARATOR
Intervention: No adjuvant systemic treatment
Number of subjects: 564
Study: 21605000

Group type: EXPERIMENTAL
Intervention: Metformin (n = 26)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Low-dose flutamide-metformin plus an oral contraceptive (PCOS women, n = 58)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Untreated (n = 13)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 97
Study: 18447762

Group type: EXPERIMENTAL
Intervention: Active intervention by drug consultation center (DCC) - information by phone, mailed written form, and text messages
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group - information given once
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 108
Study: 16487434

Group type: EXPERIMENTAL
Intervention: DHEA (50 mg p.o. daily at bedtime)
Number of subjects: 24
Study: 14509058

Group type: EXPERIMENTAL
Intervention: verum-rTMS
Number of subjects: 11

Group type: COMPARATOR
Intervention: placebo-rTMS
Number of subjects: 11
Study: 10881815

Group type: EXPERIMENTAL
Intervention: Fibroblast growth factor injected directly into the myocardium, close to the left anterior descending coronary artery.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Heat denatured fibroblast growth factor injected into the myocardium.
Number of subjects: 40
Study: 9361332

Group type: EXPERIMENTAL
Intervention: 1.0 mg haloperidol (i.v.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.5 mg haloperidol (i.v.)
Number of subjects: 0
Study: 8248606

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 33

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 33

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: All groups (Fentanyl, Halothane, Isoflurane)
Number of subjects: 33
Study: 3513472

Group type: EXPERIMENTAL
Intervention: Open biopsy of non-palpable breast lesions
Number of subjects: 314
Study: 31706728

Group type: EXPERIMENTAL
Intervention: Nursing training intervention during hospitalisation
Number of subjects: 366

Group type: COMPARATOR
Intervention: Habitual performance (control group)
Number of subjects: 366
Study: 30594122

Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 2886

Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg
Number of subjects: 2886

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2886
Study: 27554378

Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOACs)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Vitamin K Antagonists (VKAs)
Number of subjects: 51
Study: 23619813

Group type: EXPERIMENTAL
Intervention: Bluetooth headset EMFs
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mobile phone EMFs
Number of subjects: 12
Study: 22205309

Group type: EXPERIMENTAL
Intervention: Red wine (RW) with 30 g alcohol/d
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Dealcoholized red wine (DRW)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Gin with 30 g alcohol/d
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Ethanol (from RW and gin)
Number of subjects: 67